VM-26和DDP联合化疗对复发高级别脑胶质瘤的治疗体会

目的 采用替尼泊甙(teniposide,VM-26)和顺铂(cisplatin,DDP)治疗复发恶性胶质瘤,探讨其治疗效果并评价其不良反应。 方法 从2012年5月1日至2014年4月30日首都医科大学附属北京世纪坛医院,脑胶质瘤科收治的,已经过STUPP方案[术后放疗加同步替莫唑胺(temozolomide, TMZ)化疗]及之后6个疗程规范TMZ辅助化疗,经头颅MRI和/或手术后病理确诊的,复发恶性胶质瘤患者共30例,均给予VM-26联合DDP化疗。探讨其治疗效果并评价其不良反应。结果 世界卫生组织(World Health Organization,WHO)分级Ⅲ级:有效率为9.1%,生存期为43个月。WHO分级Ⅳ级:有效率为5.3%,生存期为16个月。总有效率6.67%,总生存期为18个月。 结论 VM-26联合DDP对复发高级别胶质瘤是有一定的疗效,可以选用此方案治疗复发高级别脑胶质瘤。

Treatment of high grade glioma with VM-26 and DDP in 30 cases

Objective To evaluate the safety and efficacy of teniposide (VM-26) and cisplatin (DDP) in the treatment of recurrent malignant glioma. Methods A total of 30 patients were included for this study. The patients were diagnosed with recurrent glioma between 2012/05/01 and 2014/4/30. All patients experience classical STUPP project which contains surgery resection and adjuvant radiotherapy and chemotherapy. The diagnoses were confirmed by the clinical symptoms, contrast-enhanced MRI and the consensus on histology from at least two neuropathologists at the Department of Oncology in Beijing Shijitan Hospital. After the treatment, the image based progression and the adverse events rates were applied to evaluate the results. Results The efficiency for grade Ⅲ glioma patients was 9.1%. The survival rate was 43 months. At the meanwhile, the efficiency for grade Ⅳ was 5.3% and the survival rate was 16 months. The mean overall survival rate of 30 high-grade glioma patients was 18 months. Conclusion The VM-26 and DDP are potential therapeutic agents to treat patients with high-grade malignant recurrent glioma. And VM-26 and DDP have an acceptable safety profile and its adverse events are mostly mild.